Abstract 1515: Tumor molecular profiling and spatial transcriptomics to assess colorectal cancer heterogeneity and microenvironment
Enrique Velazquez Villarreal(Keck Hospital of USC), John D. Carpten(City of Hope), Yuxin Jin(Chongqing University), Donna Loza(University of Southern California), Heinz‐Josef Lenz(USC Norris Comprehensive Cancer Center), Jing Qian(University of Massachusetts Amherst), David W. Craig(City of Hope), Brigette Waldrup(Keck Hospital of USC), Bohan Zhang(Keck Hospital of USC), Seeta Rajpara(University of Southern California)
Cited by 0
Related Papers
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Prognostic and Predictive Relevance of Primary Tumor Location in Patients With <i>RAS </i>Wild-Type Metastatic Colorectal Cancer
|JAMA Oncology|2016|722
The secreted glycoprotein lubricin protects cartilage surfaces and inhibits synovial cell overgrowth
|Journal of Clinical Investigation|2005|524